Breaking News

Almac, UCL in Metagenomics Pact

May 16, 2013

Will combine chemistry and engineering with biocatalysis expertise

The Almac biocatalysis group has secured a BBSRC (Biotechnology and Biological Sciences Research Council) program with UCL focused on metagenomics and enzyme discovery. Almac and the departments of Biochemical Engineering and Chemistry at UCL will perform the R&D work, with the input from Professors John Ward and Helen Hailes, leaders in the field of biocatalyst discovery and application. 
A limitation of biocatalysis can be the number of diverse enzymes available in a given enzyme class. Metagenomics, a culture-independent technique used to extract the total DNA from an environment, can allow access of as much as 99% of enzyme genes in environmental samples.
Dr. Tom Moody, Almac’s head of Biocatalysis & Isotope Chemistry, said, “This clearly adds further depth to our expertise and complements our recent collaboration with DSM in accessing diverse enzyme collections.”
Professor Ward remarked, “We are very excited to continue working with Almac on this prestigious project, building on many years of collaboration and partnership. Indeed, this project will see our internal capabilities further developed with true industrial needs in our vision.”

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger